Nancy Whiting, Recludix Pharma CEO
July 20, 2023 08:00 AM EDT
Financing
Startups
Deals

Fol­low­ing Dupix­ent’s rise, Sanofi heads down­stream in im­munol­o­gy for $125M small mol­e­cule pact with Re­cludix

Kyle LaHucik

Senior Reporter

As Sanofi ex­pands the reach of its block­buster Dupix­ent, the French Big Phar­ma is look­ing to go fur­ther down­stream in the IL-13 and IL-4 space …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times